Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’ – (Eye Journal AOP)

9 October 2015

This news item is available to RCOphth members only, please log in below to access.